Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cells

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44523-44537

  Ahn, Hee Jin ^a   Kim, Kwang Soo ^a   Shin, Kyung Won ^a   Lim, Kee Hwan ^a   Kim, Jin Ock ^a   Lee, Je Yong ^a   Kim, Jiewan ^a   Park, Ji Hoon ^a   Yang, Kyung Min ^a   Baek, Kwang Hyun ^a   Ko, Jeong Jae ^a   Park, Kyung Soon ^a  

^a CHA University   (South Korea)

Author keywords

Cis diamminedichloroplatinum(II) (CDDP); Ell3; Interleukin 20 (IL20); NAD(P)H quinone oxidoreductase 1 (NQO1); p53

Indexed keywords

ELEVEN NINETEEN LYSINE RICH 3 PROTEIN; INTERLEUKIN 20; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NADH QUINONE OXIDOREDUCTASE 1; PROTEASOME; PROTEIN MDM2; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); TRANSCRIPTION ELONGATION FACTOR; UBIQUITIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CISPLATIN; ELL3 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL; CHEMOSENSITIZATION; CONTROLLED STUDY; FEMALE; MCF 7 CELL LINE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; APOPTOSIS; BREAST NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PROTEIN STABILITY; RNA INTERFERENCE; TIME FACTOR; UBIQUITINATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CISPLATIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKINS; MCF-7 CELLS; NAD(P)H DEHYDROGENASE (QUINONE); PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTIONAL ELONGATION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; UP-REGULATION;

EID: 84953381357     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5972     Document Type: Article

References (24)

1. Lin C, Garruss AS, Luo Z, Guo F, Shilatifard A. The RNA Pol II elongation factor Ell3 marks enhancers in ES cells and primes future gene activation. Cell. 2013; 152:144-56.
2. Ahn HJ, Cha Y, Moon SH, Jung JE, Park KS. Ell3 enhances differentiation of mouse embryonic stem cells by regulating epithelial-mesenchymal transition and apoptosis. PLoS One. 2012; 7:e40293.
3. Wang S, El-Deiry WS. The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat Res. 2004; 119:175-87.
4. Hollander PM, Bartfai T, Gatt S. Studies on the reaction mechanism of DT diaphorase. Intermediary plateau and trough regions in the initial velocity vs substrate concentration curves. Arch Biochem Biophys. 1975; 169:568-76.
5. Asher G, Lotem J, Tsvetkov P, Reiss V, Sachs L, Shaul Y. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2003; 100: 15065-70.
6. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 2005; 19:316-21.
7. Nonaka M, Itamochi H, Kawaguchi W, Kudoh A, Sato S, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. Int J Gynecol Cancer. 2012; 22:922-9.
8. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res. 1999; 5:1007-14.
9. Wegenka UM. IL-20: biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev. 2010; 21:353-63.
10. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A, Haugen H, Jelinek L, Kelly JD, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001; 104:9-19.
11. Xu W. Interleukin-20. Int Immunopharmacol. 2004; 4:627-33.
12. Rich BE, Kupper TS. Cytokines: IL-20 - a new effector in skin inflammation. Curr Biol. 2001; 11:R531-4.
13. Chen WY, Chang MS. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol. 2009; 182:5003-12.
14. Hsieh MY, Chen WY, Jiang MJ, Cheng BC, Huang TY, Chang MS. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 2006; 7:234-42.
15. Lee SJ, Cho SC, Lee EJ, Kim S, Lee SB, Lim JH, Choi YH, Kim WJ, Moon SK. Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-kappaB) activation by inducing the up-regulation of p21(WAF1) protein expression. J Biol Chem. 2013; 288:5539-52.
16. Hsu YH, Wei CC, Shieh DB, Chan CH, Chang MS. Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol Cancer Res. 2012; 10:1430-9.
17. Ahn HJ, Kim G, Park KS. Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway. Biochem Biophys Res Commun. 2013; 437:557-64.
18. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365:671-9.
19. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol. 2005; 53:3-11.
20. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273:5858-68.
21. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2001; 98:1188-93.
22. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci U S A. 2002; 99:13125-30.
23. Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. 2000; 275:35778-85.
24. Chandel NS, Vander Heiden MG, Thompson CB, Schumacker PT. Redox regulation of p53 during hypoxia. Oncogene. 2000; 19:3840-8.